Delivery Order SPE2DB20D3103-SPE2DB25FP1K0

Award Date 6/11/25
Potential Completion Date 6/12/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,148.71, is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty medication. The contract has a completion date of June 3, 2024 and utilizes a firm-fixed price pricing type. This delivery order is part of a larger Indefinite Delivery Contract (IDC)...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,877.84 firm fixed-price contract is for the procurement of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty pharmaceutical medication. The contract has an ultimate completion date of January 3, 2025. This delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the...
This is a delivery order awarded to Amerisourcebergen Drug Corp (DUNS: TGxsdkVQRGhOYUpNR001SFhYREdNdz09) by the Defense Logistics Agency (DLA) Troop Support Medical for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a pharmaceutical product. The contract is a firm fixed-price, indefinite-delivery contract with a ceiling value of $10,523.52 and a completion date of September 17, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the...
This is a delivery order with a value of $5,261.76, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor in the United States. The order is for ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty medication. The contract has a completion date of September 5, 2024 and is a Firm Fixed Price agreement. This order is a part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which has a...
This is a $8,080.58 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a medical product, to support federal healthcare programs. The contract is not designated as a set-aside and appears to be part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with...
This is a $4,127.16 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication, with a period of performance through November 8, 2024. This delivery order is issued under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the...
This is a $13,191.68 firm fixed price delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of ACTEMRA 400 MG/20 ML VIAL 20ML. The contract has an ultimate completion date of May 19, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle with a...
This is a $6,131.04 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a pharmaceutical product, with a period of performance through June 16, 2025. The contract is not set aside and was awarded on an open competitive basis. AmerisourceBergen Drug Corp holds a larger $999,999,999.00...
This is a $4,509.00 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a specialty medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a prescription medication. The $13,785.98 firm-fixed-price contract has an ultimate completion date of August 8, 2024. Amerisourcebergen holds several indefinite delivery contracts (IDCs) with the DLA and other federal agencies, valued up to $999,999,999 and $750,000, respectively, for delivering a wide...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB25FP1K0
    Delivery Order

This is a $10,681.42 firm-fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a medical product, with an ultimate completion date of June 12, 2025. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which provides a comprehensive global pharmaceutical support vehicle through December 2026. The contract is not set-aside and allows for the delivery of a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.

Generated 9/10/25, 9:51 AM